Miao Zhou | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Miao Zhou | Precision Medicine | Best Researcher Award

Prof. Miao Zhou at Guangdong Provincial People’s Hospital, China.

Dr. Miao Zhou is a distinguished oral and maxillofacial specialist, currently serving as Chief Physician and Associate Director at the Stomatology Department of Guangdong Provincial People’s Hospital. He is also a supervisor of postgraduate and postdoctoral researchers. An innovator in oral regenerative medicine, he founded the 3D Bioprinting and Regenerative Medicine Branch of the Guangdong Society of Biomedical Engineering. His pioneering research bridges clinical practice and cutting-edge biotechnology, advancing solutions for complex craniofacial conditions. With deep expertise in biomaterials, stem cells, and exosomes, Dr. Zhou continues to drive impactful research and medical education in the fields of maxillofacial rehabilitation and tissue engineering.

Publication Profile 

Scopus

Education

Dr. Miao Zhou earned his Ph.D. in 2009 from Peking University, one of China’s top-tier institutions, where he focused on maxillofacial rehabilitation using functional biomaterials and tissue engineering. His doctoral thesis explored clinical solutions for oral and maxillofacial defects through bio-integrative materials and scaffold systems. This strong academic foundation laid the groundwork for his later interdisciplinary innovations in regenerative medicine. In addition to his formal education, Dr. Zhou has participated in numerous continuing education programs and scientific collaborations, refining his expertise in 3D printing, stem cell therapy, and implantology, and training the next generation of specialists in advanced dental medicine.

Experience

With over 15 years of clinical and research experience, Dr. Miao Zhou is a Chief Physician and Associate Director at Guangdong Provincial People’s Hospital’s Stomatology Department. He supervises both postgraduates and postdocs, guiding translational research in tissue regeneration. He has served as Principal Investigator on numerous national and provincial-level projects, especially in the application of 3D-printed biomimetic scaffolds and exosomes. As a research leader, Dr. Zhou has pioneered innovations in craniomaxillofacial bone regeneration and soft tissue reconstruction. His clinical expertise, combined with academic leadership, positions him as a key influencer in oral regenerative therapy and personalized medical biomaterial development.

Awards 

Dr. Zhou has received numerous accolades, including the First Prize for Excellent Paper at the 6th China International & 9th China Academic Conference of Oral and Maxillofacial Surgery. His recognition reflects significant contributions to clinical and translational research. He has been honored by national bodies such as the National Natural Science Foundation of China and the Guangzhou Healthcare Innovation Program for his leadership in 3D bioprinting and regenerative medicine. As the founder of the 3D Bioprinting and Regenerative Medicine Branch under the Guangdong Society of Biomedical Engineering, his efforts have helped shape emerging medical frontiers and drive collaborative innovation.

Research Focus 

Dr. Zhou’s research centers on 3D-printed biomimetic scaffolds, stem cell therapy, and exosome-based interventions for oral and maxillofacial regeneration. His work explores how engineered tissues and cell-based therapies can reconstruct large jaw defects, restore bone function, and integrate with host tissues. His studies focus on osteoinduction, vascularization, and personalized medicine approaches using biocompatible materials. By leveraging cutting-edge printing technologies and biomolecular signaling pathways, Dr. Zhou aims to bridge gaps between laboratory research and clinical application—delivering impactful solutions for tissue repair and oral implantology. His interdisciplinary approach integrates biomaterials science, dentistry, and regenerative medicine to redefine patient care.

Publication Top Notes

  • An engineered M2 macrophage-derived exosomes-loaded electrospun biomimetic periosteum promotes cell recruitment, immunoregulation, and angiogenesis in bone regeneration
  • Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties
  • 3WJ RNA Nanoparticles-Aptamer Functionalized Exosomes From M2 MacrophagesTarget BMSCs to Promote the Healing of Bone Fractures

Tao Lv | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Tao Lv | Personalized Medicine | Best Researcher Award

Prof. Tao Lv at Qilu Hospital of Shandong University Dezhou Hospital, China.

Dr. Tao Lv is a dedicated and forward-thinking medical researcher specializing in plastic and reconstructive surgery, regenerative medicine, and dermatological science. With a profound interest in wound healing, scar formation, and stem cell therapies, Dr. Lv has actively contributed to advancing medical knowledge through impactful clinical studies and translational research. His multidisciplinary collaborations have yielded significant breakthroughs in scar prevention and fat grafting techniques, offering new hope to patients undergoing reconstructive procedures. He has co-authored peer-reviewed publications in top-tier journals such as Annals of Plastic Surgery, Aesthetic Plastic Surgery, Stem Cells Translational Medicine, and Frontiers in Cell and Developmental Biology. Driven by scientific rigor and patient-focused innovation, Dr. Lv continues to explore bioactive molecules and cellular therapies to improve outcomes in tissue engineering and plastic surgery. His work is not only appreciated in academia but also among practicing clinicians for its direct application in enhancing post-operative care and long-term patient satisfaction.

Publication Profile 

Scopus

Education

Dr. Tao Lv holds a Ph.D. in a medical or biomedical science discipline (exact major not specified), providing him with an advanced understanding of molecular biology, tissue regeneration, and clinical methodologies. He likely earned his bachelor’s and master’s degrees in related fields such as biology, medicine, or biomedical engineering. During his academic journey, he developed strong expertise in cellular mechanisms, biochemistry, and clinical trial design, which laid the foundation for his success in regenerative and reconstructive medicine. Dr. Lv’s academic training emphasized interdisciplinary research, laboratory techniques, and translational approaches to tackle real-world clinical challenges. As reflected in his publications, he worked closely with both research and clinical departments, blending scientific exploration with practical outcomes in surgery and therapeutics. His academic milestones have been integral to his capacity to lead and collaborate in cutting-edge studies. Dr. Lv’s educational background not only sharpened his technical competencies but also fostered a deep appreciation for patient-centric research.

Experience

Dr. Tao Lv has amassed considerable experience in biomedical and clinical research, focusing particularly on scar modulation, fat grafting, and mesenchymal stem cell behavior. His professional journey includes roles in both academic institutions and clinical research settings, where he collaborated with surgeons, dermatologists, and biomedical scientists. One of his standout contributions was exploring the dose-dependent effects of Botulinum Toxin Type A in scar prevention across different body regions—an innovative, randomized controlled trial published in 2025. He has also been part of a research team examining differences in human skin and hypertrophic scar tissue based on age, location, and maturity, further emphasizing his commitment to personalized and patient-specific medical solutions. In 2019, his work on using Fructose 1,6-Bisphosphate as a protective agent in experimental fat grafting marked a breakthrough in stem cell translational therapy. He has also investigated how CXCL2 affects mesenchymal stem cell function in high-fat diet-fed rats, bridging metabolic health with regenerative biology. Through his roles, Dr. Lv has gained expertise in clinical study design, patient care, molecular diagnostics, and regenerative interventions. His integrative approach helps bridge the gap between bench and bedside.

Awards 

While specific awards and honors are not mentioned in the provided content, Dr. Tao Lv’s prolific publication history in high-impact, peer-reviewed journals suggests he is a highly respected figure in the fields of regenerative medicine and plastic surgery research. His studies have likely earned recognition in national and international medical symposia and research forums. The consistent quality and relevance of his work—including randomized controlled trials and translational stem cell therapies—imply nominations or receipt of research grants, young investigator awards, or conference best-paper recognitions. Publications in prestigious journals like Stem Cells Translational Medicine, Aesthetic Plastic Surgery, and Annals of Plastic Surgery reflect his status as a thought leader. Given his multi-institutional collaborations and interdisciplinary approach, Dr. Lv is likely affiliated with academic or hospital research institutions that value innovation and clinical impact. His honors may include acknowledgments for advancing scar treatment, improving cosmetic outcomes post-surgery, and exploring metabolic impacts on cell biology. Future accolades may further solidify his legacy as a pioneer in integrating stem cell therapy and scar modulation into clinical practice.

Research Focus 

Dr. Tao Lv’s research is deeply rooted in regenerative medicine, scar prevention, and the application of biologics in aesthetic and reconstructive procedures. He focuses on understanding tissue response in hypertrophic scarring and identifying therapeutic interventions using agents like Botulinum Toxin Type A. One of his major research interests includes fat grafting, where he explored the protective effects of Fructose 1,6-Bisphosphate to enhance graft viability. Another vital area of his work investigates how CXCL2 impairs mesenchymal stem cell function, particularly under high-fat dietary conditions, merging insights from metabolic disease and cell biology. Dr. Lv is also dedicated to comparative tissue analysis—such as assessing skin versus scar tissue across age groups and anatomical sites—to inform personalized treatment strategies. His translational approach combines bench-side discoveries with patient-centered outcomes. By using clinical trial methodologies and molecular tools, he addresses both acute and chronic issues in surgical healing and tissue regeneration. Overall, his research aims to enhance healing, reduce fibrosis, and improve long-term cosmetic and functional outcomes, making a significant impact on the fields of plastic surgery and tissue engineering.

Publication Top Notes

  • Dose-Dependent Effects of Botulinum Toxin Type A on Prevention of Postoperative Scars in Various Regions in the Body: A Prospective, Double-Blind Randomized Controlled Trial

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

KYU SHIK MUN | Personalized Medicine | Best Researcher Award

Assist. Prof. Dr. KYU SHIK MUN, Cedars-Sinai Medical Center, United States

Assist. Prof. Dr. Kyu Shik Mun is a distinguished researcher in cystic fibrosis (CF) and biomedical engineering 🧬. As a Principal Investigator and Co-Director, he has led groundbreaking projects on CF-related diabetes, organ-on-a-chip models, and personalized CF therapy 🏥. His work, funded by organizations like the Cystic Fibrosis Foundation and Vertex Pharmaceuticals, has yielded significant patents and high-impact publications 📑. With 733 citations, an h-index of 10, and an i10-index of 10, Dr. Mun continues to drive innovations in CF research, bridging biomedical science and translational medicine 🔬.

Publication Profile

Google Scholar

Professional Background

Assist. Prof. Dr. Kyu Shik Mun earned his Ph.D. in the Materials Science and Engineering Program at the University of Cincinnati 🎓. In 2016, he joined the Cystic Fibrosis Research Center at Cincinnati Children’s Hospital, where he pioneered a microfluidic-based organ-on-chip program from scratch 🏥🧬. His groundbreaking research focused on studying cystic fibrosis and related disorders. In 2021, he was promoted to Assistant Professor at Cedars-Sinai 🏆, where he continues to advance in vitro cell culture models using organ-on-chip technology and 3D bioprinting 🖨️🔬, contributing to innovative solutions in biomedical research and personalized medicine.

Awards

Assist. Prof. Dr. Kyu Shik Mun has received numerous prestigious honors and awards throughout his academic and professional journey 🎖️. He was awarded multiple Outstanding Grade Scholarships at Gangneung National University 🏅 (2000–2009) and recognized for excellence with department and presidential awards 🏆. His achievements include a scholarship from the Korean Broadcasting System 📺 and the Korea Research Foundation 🌏. During his Ph.D. at the University of Cincinnati, he earned a University Graduate Scholarship 🎓 (2010–2014). His research has been recognized by the American Gastroenterological Association and the Cystic Fibrosis Foundation 🧬, receiving multiple Best Abstract and Early Career Investigator awards (2017–2024) 🥇.

Experience 

Assist. Prof. Dr. Kyu Shik Mun has been actively involved in non-clinical teaching, contributing to journal clubs and lab mentoring 📚🎤. He has delivered key presentations on organ-on-a-chip technology 🧬, including talks at Cincinnati Children’s Hospital (2020) and Cedars-Sinai (2021) 🏥. His mentorship spans postdoctoral fellows, research associates, and Ph.D. students, guiding projects in 3D bioprinting 🖨️ and patient-derived lung-on-a-chip models 🌬️. Since 2016, he has mentored 15 summer and rotation students—including high school, college, Ph.D., and MD candidates—on fabricating organ-on-a-chips and culturing cells, fostering the next generation of biomedical researchers 🔬.

Research Focus

Assist. Prof. Dr. Kyu Shik Mun’s research primarily focuses on nanotechnology 🧪, biosensors 🧫, and biomedical engineering 🏥. His work spans optical interferometric biosensors for label-free detection, organ-on-a-chip models for diseases like cystic fibrosis 🫁, and TiO₂ nanotube arrays for applications in solar cells ☀️ and photocatalysis. He also explores drug discovery 💊 by targeting molecular pathways in cystic fibrosis and related disorders. His interdisciplinary research integrates materials science 🏗️, biophysics ⚛️, and microfluidics 🔬 to develop innovative medical technologies, aiming to advance precision medicine 🎯 and renewable energy solutions 🌱.

Publication Top Notes

A Stable, Label-free Optical Interferometric Biosensor Based on TiO2 Nanotube Arrays

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders

Guided construction of single cell reference for human and mouse lung

Targeting the pregnane X receptor using microbial metabolite mimicry

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations

Surface passivation of highly ordered TiO2 nanotube arrays and application to dye-sensitized solar cells using the concept of isoelectric point

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR

Guanylate cyclase 2C agonism corrects CFTR mutants

Cystic Fibrosis Human Organs-on-a-Chip

Prof. Dr. Federico Hawkins|Personalized Medicine|Excellence in Research

Published on by Top Pharmaceutical

Prof. Dr. Federico Hawkins-Personalized Medicine-Excellence in Research

Prof. Dr. Federico Hawkins at Universidad Complutense Madrid ,Spain

Author Profile

Scopus

🎓 Early Academic Pursuits

Federico Gilberto Hawkins Carranza embarked on a remarkable academic journey in the field of medicine, earning his General Physician degree from the University of Salamanca in 1969. This was followed by his pursuit of higher education, where he completed a Ph.D. thesis titled “Mechanism of Action of Gastrointestinal Hormones upon Pancreas” under the mentorship of Prof. Dr. Manuel Serrano Ríos at the University Autónoma of Madrid in 1978.

During this period, Dr. Hawkins also obtained a Diploma in Psychology from the Pontifical University of Salamanca (1969) and completed his Internship and Residency at Fundación Jiménez Díaz (1969–1972), specializing in Internal Medicine and Endocrinology in 1973. His thirst for knowledge led him to prestigious institutions worldwide through scholarships, including the Endocrine Unit at Hammersmith Hospital in London (1977) and the Transplant Unit at Minnesota University (1980).

💼 Professional Endeavors

Dr. Hawkins began his illustrious career as a physician in the Service of Endocrinology at University Hospital 12 de Octubre, Madrid, in 1973. By 1979, he rose to the position of Chief of Service of Endocrinology, a role he held until 2016. His contributions to clinical endocrinology were instrumental in shaping the department into a hub of innovation and excellence.

Parallel to his clinical work, Dr. Hawkins was an active academician. In 1978, he was appointed Professor of Medicine at Complutense University of Madrid and eventually became the Chairman of Medicine in 2000. Post-retirement, he continued to serve as a Consultant at the Research Institute i+12 at University Hospital 12 de Octubre.

🔬 Contributions and Research Focus

Dr. Hawkins made pioneering contributions to endocrinology, focusing on diabetes, thyroid diseases, and postmenopausal osteoporosis.

Diabetes Mellitus:

  • Developed and implemented Radioimmunoassays (RIA) for insulin and glucagon in Spain.
  • Conducted studies on insulin secretion in chromosomal disorders, including Klinefelter’s and Down syndromes.
  • Demonstrated the hypoglycemic effects of fig tree decoctions in animals and humans.

Thyroid Diseases:

  • Advanced the understanding of thyrocalcitonin fractions in neoplasia and thyroid cancer.
  • Investigated the relationship between TSH suppression and bone mass.

Postmenopausal Osteoporosis:

  • Played a key role in clinical trials for drugs such as Alendronate, Risedronate, Teriparatide, and Strontium Ranelate.
  • Actively participated in drafting the Spanish Guide for Osteoporosis, contributing to patient care protocols.

🏆 Accolades and Recognition

Dr. Hawkins’ expertise and leadership were widely acknowledged:

  • He was appointed as an Academician Correspondent at the Royal Academy of Medicine in 2017.
  • Received honorary titles such as Extraordinary Professor at the Faculty of Medicine in Panama (2016).
  • Served as the Director of the Revista Española de Enfermedades Metabólicas and a reviewer for prestigious journals, including Current Medical Research & Opinion.

🌍 Impact and Influence

Dr. Hawkins significantly influenced the global medical community through his research and teaching. His studies on bone mass in diabetics and early markers of bone loss have been foundational in advancing treatment strategies. As an academician, he nurtured generations of physicians and researchers, promoting excellence in clinical endocrinology.

🏛️ Legacy and Future Contributions

Even in retirement, Dr. Hawkins remains a towering figure in endocrinology. His dedication to patient care, innovative research, and teaching has left a lasting legacy. His work on endocrine disorders, especially diabetes and osteoporosis, continues to shape clinical practices worldwide. Dr. Hawkins also actively contributes to medical guidelines and collaborates with researchers globally, ensuring his insights continue to benefit humanity.

Notable Publication

Socioeconomic status, osteoporosis and fragility fractures | Estatus socioeconómico, osteoporosis y fracturas por fragilidad

  • Authors   : Martínez-Díaz-Guerra, G., Hawkins Carranza, F., Librizzi, S.
  • Year         :2024

Health-Related Quality of Life Long-Term Study in Lung Transplant Patients: A Single-Center Experience

      • Authors   : Monteagudo, L.J., Diaz-Guerra, G.M., Badillo, A.Á., … Arriscado, C.M., Hawkins Carranza, F.
      • Year         :2024

Comparison of Bone Mineral Density and Trabecular Bone Score in Patients with and without Vertebral Fractures and Differentiated Thyroid Cancer with Long-Term Serum Thyrotrophin-Suppressed Therapy

  • Authors   : Hawkins Carranza, F., Arroba, C.M.-A., López Alvarez, M.B., Librizzi, S., Martínez Díaz Guerra, G.

Incidence of type 2 diabetes in the elderly in Central Spain: Association with socioeconomic status, educational level, and other risk factors

  • Authors   :Hawkins Carranza, F., Corbatón-Anchuelo, A., Bermejo Pareja, F., … Benito-León, J., Serrano-Ríos, M.
  • Journal     : Primary Care Diabetes
  • Year         :2022                                                                                                                                                                                                                                                                                                                                                                                                           

Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer

  • Authors   :Hawkins Carranza, F., Guadalix Iglesias, S., De Mingo Dominguez, M.L., … Alvares, B.L., Martínez Diaz-Guerra, G.